Aurobindo Pharma Limited

NSEI:AUROPHARMA Stock Report

Market Cap: ₹721.2b

Aurobindo Pharma Past Earnings Performance

Past criteria checks 4/6

Aurobindo Pharma's earnings have been declining at an average annual rate of -5.3%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 5.1% per year. Aurobindo Pharma's return on equity is 11.6%, and it has net margins of 11.8%.

Key information

-5.3%

Earnings growth rate

-5.3%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate5.1%
Return on equity11.6%
Net Margin11.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Is Aurobindo Pharma (NSE:AUROPHARMA) Using Too Much Debt?

Dec 18
Is Aurobindo Pharma (NSE:AUROPHARMA) Using Too Much Debt?

Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Nov 12
Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Oct 20
Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Sep 10
Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Aug 23
This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Aug 13
Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Jun 20
Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29
Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

May 22
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Apr 10
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Jan 14
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Dec 27
Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Revenue & Expenses Breakdown

How Aurobindo Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NSEI:AUROPHARMA Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24302,95035,81643,1790
30 Jun 24297,18435,21441,6330
31 Mar 24290,01931,73040,4340
31 Dec 23278,94727,70538,8230
30 Sep 23269,50023,25438,1430
30 Jun 23254,70019,77737,2780
31 Mar 23248,55419,27536,5600
31 Dec 22241,91819,97736,4780
30 Sep 22237,86921,11235,9500
30 Jun 22239,89423,98735,8540
31 Mar 22234,55526,48235,7510
31 Dec 21236,47628,67635,7460
30 Sep 21240,10352,10935,8650
30 Jun 21245,51853,21736,3950
31 Mar 21247,74653,34836,5760
31 Dec 20249,31653,83136,5910
30 Sep 20244,61731,42135,7610
30 Jun 20235,78729,75734,4140
31 Mar 20230,98528,45133,3330
31 Dec 19222,32325,66632,2240
30 Sep 19216,07025,73330,7440
30 Jun 19207,57925,44929,2260
31 Mar 19195,63623,64727,3890
31 Dec 18183,83423,07825,6320
30 Sep 18174,24621,90624,5410
30 Jun 18171,09123,60323,4730
31 Mar 18164,63024,23222,4140
31 Dec 17159,38124,27120,9030
30 Sep 17154,90324,10719,9530
30 Jun 17148,27922,35219,0320
31 Mar 17149,33423,01718,4510
31 Dec 16151,56522,80917,7990
30 Sep 16147,55922,46617,3590
30 Jun 16143,44620,94516,8230
31 Mar 16138,16220,25116,0190
31 Dec 15133,24918,23028,438894
30 Sep 15129,95616,72427,775894
30 Jun 15125,43315,92826,938894
31 Mar 15121,34015,75813,5480
31 Dec 14112,82516,73817,756624
30 Sep 14102,75617,06916,210624
30 Jun 1493,10915,69714,800624
31 Mar 1481,00211,72913,273624
31 Dec 1373,7367,79712,261423

Quality Earnings: AUROPHARMA has high quality earnings.

Growing Profit Margin: AUROPHARMA's current net profit margins (11.8%) are higher than last year (8.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: AUROPHARMA's earnings have declined by 5.3% per year over the past 5 years.

Accelerating Growth: AUROPHARMA's earnings growth over the past year (54%) exceeds its 5-year average (-5.3% per year).

Earnings vs Industry: AUROPHARMA earnings growth over the past year (54%) exceeded the Pharmaceuticals industry 20.4%.

Return on Equity

High ROE: AUROPHARMA's Return on Equity (11.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 04:21
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aurobindo Pharma Limited is covered by 54 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Meeta ShettyAsian Markets Securities Private Limited
Kamlesh KotakAsian Markets Securities Private Limited
Harith AhamedAvendus Spark